Mark C. Schneyer - 01 May 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Reporting relationship: EVP, CHIEF FINANCIAL OFFICER
Issuer ticker: ACAD
Reported as of: 01 May 2026
Net transaction value: -$76,396
SEC form: 4
Accepted by SEC: 05 May 2026, 18:00:18 UTC
Prior SEC filing: 07 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact

Key filing fact

Mark C. Schneyer filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 05 May 2026.

Key facts

This page summarizes Mark C. Schneyer's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 May 2026, 18:00.

Change

Previous filing in this sequence was filed on 07 Apr 2026.
Current net transaction value: -$76,396.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001899977 Primary reporting owner

Schneyer Mark C.

Relationship: EVP, CHIEF FINANCIAL OFFICER
Address: C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Signature date: 05 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACAD transaction

Common Stock

Options Exercise

Transaction value
Shares: +6,815
Change %: +11%
Price
Shares after: 69,651
Date: 01 May 2026
Ownership: Direct
Footnotes: F1

ACAD transaction

Common Stock

Sale

Transaction value: $76,396
Shares: -3,506
Change %: -5%
Price: $21.79
Shares after: 66,145
Date: 04 May 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACAD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -6,815
Change %: -50%
Price: $0.000000^*
Shares after: 6,815
Date: 01 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,815
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $21.7932, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F4

The restricted stock units vest in four equal annual installments beginning May 1, 2024.